Indian pharmaceutical company Akums Drugs and Pharmaceuticals has partnered with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for research and development of a range of products for multiple therapies. 

This association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner, the company said in a statement on Wednesday.

The tripartite association will see Akums manufacture and commercialise the products created by Leiutis Pharmaceuticals LLP and API from Biophore, the statment added.

"The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years, Akums said in the statement. 

“I am excited to know that Leiutis, Biophore and Akums have collaborated to introduce such differentiated and speciality products. The entire process, from basic Research API Development and Product Manufacturing is based in India. This is exactly what is exciting for India and expected from Indian entrepreneurs,” said Dr Y.K Gupta, President of AIIMS Bhopal and President AIIMS Jammu and Former Dean and HoD Pharmacology, AIIMS Delhi who was present at the launch.

"A significantly large number of patients suffer from these diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options. In association with Leitus and Biophore, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes," said Sanjeev Jain, Founder, Promoter and Director, Akums. 

Dr Jagadeesh Babu Rangisetty, Founder and CEO of Biophore said that it is imperative to form such partnerships to bring innovative products to the medical fraternity and patients. "It's such an exciting prospect to partner with two other amazing organisations in the global pharma space. The aim is to combine our key competencies, capacities, and our passion for providing new therapies globally proven through clinical outcomes and to improve the lives of patients", he said.

"Innovative therapies should address two objectives; ameliorate suffering and improve quality of life. Innovation is a collaborative journey and I am very excited to be part of this journey. I am overwhelmed with the impact this association will make by creating value through clinically proven innovations for healthcare providers and patients," said K Chandrasekhar, CEO of Leiutis Pharmaceuticals LLP.